Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated on 12th September 1990, AEterna is a Canadian biopharmaceutical company focused on the
development of new therapeutics for unmet medical needs, principally cancer. AEterna's lead compound in
development, Neovastat (AE-941), is a new orally-bioavailable product which seeks to inhibit the growth and
proliferation of diseases complicated by angiogenesis by blocking new blood vessel development. Neovastat is being
investigated in three fields: oncology, dermatology and ophthalmology.